Skip to content
value.today

AZTherapies, INC

🇺🇸 Boston, Massachusetts, USAPharmaceuticalsFounded 2011
Total raised
$79 M
7 rounds on record
Latest round
$15 M
Aug 2020
First round on record
Dec 2014
Today
Private
No later event on record

Funding rounds

7 counted as startup funding. Open the number of investors for the round's details.

Funding rounds of AZTherapies, INC
MonthRaisedRaiseSizeInvestorsSoldFiling
Aug 2020$15 MNo. 7$10 to $50 million

AZTherapies, INC: Raise no. 7, Aug 2020

Investors in this round

59 investors had bought by the notice of Sep 15, 2020: 59 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$15 M of $35 M offered; $20 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Brian Bartlett · Executive Officer
  • David Elmaleh · Executive Officer, Director
  • Karen Reeves · Executive Officer
  • David Taft · Director
  • George Behrakis · Director
  • Gillian Sandler · Director
  • Keith Greenfield · Director
  • Noah Gottdiener · Director
  • Peter Conti · Director
  • Thierry Porte · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Brian Bartlett, Cfo. Source: SEC Form D, newest notice filed Sep 15, 2020. Read the notice at the SEC.

equitySEC
Jun 2019$19 MNo. 6$10 to $50 million

AZTherapies, INC: Raise no. 6, Jun 2019

Investors in this round

25 investors had bought by the notice of Jul 12, 2019: 25 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$19 M of $38 M offered; $18 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Brian T. Bartlett · Executive Officer
  • David R.. Elmaleh · Executive Officer, Director
  • Jay T. Mohr · Executive Officer
  • Karen T. Reeves · Executive Officer
  • Robert S. Warren · Executive Officer
  • David S. Taft · Director
  • George T. Behrakis · Director
  • Gillian T. Sandler · Director
  • Keith S. Greenfield · Director
  • Peter S. Conti · Director
  • Ronald S. Tompkins · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Remarks in the notice

  • On the amounts: “Amount sold includes the conversion of $6,415,174 of convertible notes in the equity issued in the transaction.”

Signed by David Elmaleh, Chairman. Source: SEC Form D, newest notice filed Jul 12, 2019. Read the notice at the SEC.

equitySEC
May 2019$6 MNo. 5$2 to $10 million

AZTherapies, INC: Raise no. 5, May 2019

Investors in this round

11 investors had bought by the notice of May 31, 2019: 11 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$6 M of $8 M offered; $2 M still to sell
Smallest investment taken
no minimum stated
What was sold
debt, options or other rights to buy securities
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • David R. Elmaleh · Executive Officer, Director
  • Karen S. Reeves · Executive Officer
  • Keith S. Greenfield · Executive Officer, Director
  • Robert S. Warren · Executive Officer
  • David S. Taft · Director
  • Gillian S. Sandler · Director
  • John S. Porter · Director
  • Peter S. Conti · Director
  • Ronald S. Tompkins · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Remarks in the notice

  • On the use of proceeds: “No payments have been proposed other than payments of salaries in the ordinary course of business.”

Signed by David R. Elmaleh, Ph.D., Chief Executive Officer. Source: SEC Form D, newest notice filed May 31, 2019. Read the notice at the SEC.

debt, optionsSEC
Jun 2018$16 MNo. 4$10 to $50 million

AZTherapies, INC: Raise no. 4, Jun 2018

Investors in this round

35 investors had bought by the notice of Oct 16, 2018: 35 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$16 M of $25 M offered; $9 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity, options or other rights to buy securities
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • David R. Elmaleh · Executive Officer, Director
  • Karen S. Reeves · Executive Officer
  • Keith S. Greenfield · Executive Officer, Director
  • Robert S. Warren · Executive Officer
  • David S. Taft · Director
  • Gillian S. Sandler · Director
  • John S. Porter · Director
  • Peter S. Conti · Director
  • Ronald S. Tompkins · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Remarks in the notice

  • On the amounts: “Amount offered and sold does not include the conversion of Convertible Promissory Notes in connection with the Initial Closing of the Financing.”
  • On the use of proceeds: “No payments have been proposed other than payments of salaries in the ordinary course of business.”

Signed by David R. Elmaleh, Ph.D., Chief Executive Officer. Source: SEC Form D and 1 amendment, newest notice filed Oct 16, 2018. Read the notice at the SEC.

equity, optionsSEC
Dec 2017$2 MNo. 3Under $2 million

AZTherapies, INC: Raise no. 3, Dec 2017

Investors in this round

9 investors had bought by the notice of Dec 18, 2017: 9 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$2 M of $6 M offered; $4 M still to sell
Smallest investment taken
no minimum stated
What was sold
debt, options or other rights to buy securities
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • David R. Elmaleh · Executive Officer, Director
  • Keith S. Greenfield · Executive Officer, Director
  • Robert S. Warren · Executive Officer
  • David S. Taft · Director
  • John S. Porter · Director
  • Peter S. Conti · Director
  • Ronald S. Tompkins · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Remarks in the notice

  • On the use of proceeds: “No payments have been proposed other than payments of salaries in the ordinary course of business.”

Signed by David Elmaleh, Chairman and CEO. Source: SEC Form D, newest notice filed Dec 18, 2017. Read the notice at the SEC.

debt, optionsSEC
Nov 2015$16 MNo. 2$10 to $50 million

AZTherapies, INC: Raise no. 2, Nov 2015

Investors in this round

41 investors had bought by the notice of Feb 6, 2017: 41 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$16 M of $20 M offered; $4 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity, options or other rights to buy securities
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
more than a year
Issuer's revenue
No revenue
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • David R. Elmaleh · Executive Officer, Director
  • Keith S. Greenfield · Executive Officer, Director
  • Robert S. Warren · Executive Officer
  • David S. Taft · Director
  • John S. Porter · Director
  • Peter S. Conti · Director
  • Ronald S. Tompkins · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Remarks in the notice

  • On the use of proceeds: “No payments have been proposed other than payments of salaries in the ordinary course of business.”

Signed by Oded Kadosh, Secretary. Source: SEC Form D and 1 amendment, newest notice filed Feb 6, 2017. Read the notice at the SEC.

equity, optionsSEC
Dec 2014$6 MNo. 1$2 to $10 million

AZTherapies, INC: Raise no. 1, Dec 2014

Investors in this round

15 investors had bought by the notice of Jan 6, 2015: 15 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$6 M of $13 M offered; $7 M still to sell
Smallest investment taken
$25,000
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
No revenue
Sales commissions
none
Finders' fees
none
Paid to its own people
$150,000 (proceeds used for payments to executives, directors or promoters)
Estimates
the notice marks payments to its own people as estimates
The company
Corporation, incorporated in Delaware

People named in the notice

  • David R Elmaleh · Executive Officer, Director
  • John R Porter · Director
  • Keith R Greenfield · Director
  • Peter R Conti · Director
  • Ronald R Tompkins · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Oded Kadosh, Secretary. Source: SEC Form D, newest notice filed Jan 6, 2015. Read the notice at the SEC.

equitySEC

Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.

How it makes money#

What its filings and its own website say, sentence by sentence, each with its source.

  • AZTherapies, INC chose not to state its revenue in its newest notice of a funding round (Sep 2020).

    SEC Form D · Sep 2020

  • The industry group it chose in its notices: Pharmaceuticals.

    SEC Form D · Sep 2020

That is all the official record says: AZTherapies, INC has not published its revenue in a filing we can read, and no other official source covers it. Revenue figures come from crowdfunding filings (SEC Form C) and from annual reports once a company is listed.

Products and services#

No products or services on record: no website is on record for it in an official source (its SEC filings, Wikidata).

Investors#

No investor of AZTherapies, INC is named in an official source we use. Its funding notices give only how many investors bought, not who they are.

Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 7 rounds above had up to 59 investors.

Executives and directors

As the company named them in its notices. Directors of a funded startup are often partners of its investors.

People named by AZTherapies, INC
NameRoleNamed in
Brian BartlettExecutive officerSep 2020
David ElmalehExecutive officerSep 2020
Karen ReevesExecutive officerSep 2020
Brian T. BartlettExecutive officerJul 2019
David R.. ElmalehExecutive officerJul 2019
Jay T. MohrExecutive officerJul 2019
Karen T. ReevesExecutive officerJul 2019
Robert S. WarrenExecutive officerJul 2019
David R. ElmalehExecutive officerMay 2019
Karen S. ReevesExecutive officerMay 2019
Keith S. GreenfieldExecutive officerMay 2019
David R ElmalehExecutive officerJan 2015
David ElmalehDirectorSep 2020
David TaftDirectorSep 2020
George BehrakisDirectorSep 2020
Gillian SandlerDirectorSep 2020
Keith GreenfieldDirectorSep 2020
Noah GottdienerDirectorSep 2020
Peter ContiDirectorSep 2020
Thierry PorteDirectorSep 2020
David R.. ElmalehDirectorJul 2019
David S. TaftDirectorJul 2019
George T. BehrakisDirectorJul 2019
Gillian T. SandlerDirectorJul 2019
Keith S. GreenfieldDirectorJul 2019
Peter S. ContiDirectorJul 2019
Ronald S. TompkinsDirectorJul 2019
David R. ElmalehDirectorMay 2019
Gillian S. SandlerDirectorMay 2019
John S. PorterDirectorMay 2019
David R ElmalehDirectorJan 2015
John R PorterDirectorJan 2015
Keith R GreenfieldDirectorJan 2015
Peter R ContiDirectorJan 2015
Ronald R TompkinsDirectorJan 2015